Balyasny Asset Management L.P. Sells 20,902 Shares of Enovis Co. (NYSE:ENOV)

Balyasny Asset Management L.P. lowered its stake in Enovis Co. (NYSE:ENOV - Free Report) by 75.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 6,807 shares of the company's stock after selling 20,902 shares during the quarter. Balyasny Asset Management L.P.'s holdings in Enovis were worth $299,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ENOV. Aster Capital Management DIFC Ltd bought a new position in shares of Enovis during the fourth quarter valued at approximately $29,000. Quadrant Capital Group LLC lifted its stake in Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after acquiring an additional 239 shares during the period. UMB Bank n.a. lifted its stake in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after acquiring an additional 437 shares during the period. Quarry LP lifted its stake in Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after acquiring an additional 749 shares during the period. Finally, Sterling Capital Management LLC lifted its stake in Enovis by 56.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock worth $143,000 after acquiring an additional 1,173 shares during the period. Institutional investors own 98.45% of the company's stock.

Enovis Stock Down 2.3%

ENOV traded down $0.76 during trading on Friday, reaching $31.61. The stock had a trading volume of 692,977 shares, compared to its average volume of 786,005. The stock's 50 day moving average is $34.73 and its two-hundred day moving average is $41.10. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -14.43 and a beta of 1.79. Enovis Co. has a one year low of $29.32 and a one year high of $51.00.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. The business had revenue of $558.83 million during the quarter, compared to the consensus estimate of $558.80 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm's quarterly revenue was up 8.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.50 earnings per share. As a group, analysts expect that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. JMP Securities dropped their price target on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group dropped their price target on Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Needham & Company LLC dropped their price target on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $58.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.